All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT). A Randomized, Double-Blind, Placebo-Controlled Trial

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F11%3AN0000001" target="_blank" >RIV/00098892:_____/11:N0000001 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216224:14110/11:00055476 RIV/61988987:17110/11:A12014HT RIV/61989592:15110/11:73598555

  • Result on the web

    <a href="https://www.ahajournals.org/doi/pdf/10.1161/HYPERTENSIONAHA.111.169961" target="_blank" >https://www.ahajournals.org/doi/pdf/10.1161/HYPERTENSIONAHA.111.169961</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.169961" target="_blank" >10.1161/HYPERTENSIONAHA.111.169961</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT). A Randomized, Double-Blind, Placebo-Controlled Trial

  • Original language description

    There is currently limited data on which drug should be used to improve blood pressure (BP) control in patients with resistant hypertension. This study was designed to assess the effect of the addition of 25 mg of spironolactone on BP in patients with resistant arterial hypertension. Patients with office systolic BP >140 mm Hg or diastolic BP >90 mm Hg despite treatment with at least 3 antihypertensive drugs, including a diuretic, were enrolled in this double-blind, placebo-controlled, multicenter trial. One hundred seventeen patients were randomly assigned to receive spironolactone (n=59) or a placebo (n=58) as an add-on to their antihypertensive medication, by the method of simple randomization. Analyses were done with 111 patients (55 in the spironolactone and 56 in the placebo groups). At 8 weeks, the primary end points, a difference in mean fall of BP on daytime ambulatory BP monitoring (ABPM), between the groups was −5.4 mm Hg (95%CI −10.0; −0.8) for systolic BP (P=0.024) and −1.0 mm Hg (95% CI −4.0; 2.0) for diastolic BP (P=0.358). The APBM nighttime systolic, 24-hour ABPM systolic, and office systolic BP values were significantly decreased by spironolactone (difference of −8.6, −6.6, and −6.5 mm Hg; P=0.011, 0.004, and 0.011), whereas the fall of the respective diastolic BP values was not significant (−3.0, −1.0, and −2.5 mm Hg; P=0.079, 0.405, and 0.079). The adverse events in both groups were comparable. In conclusion, spironolactone is an effective drug for lowering systolic BP in patients with resistant arterial hypertension.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30201 - Cardiac and Cardiovascular systems

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2011

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Hypertension

  • ISSN

    0194-911X

  • e-ISSN

    1524-4563

  • Volume of the periodical

    57

  • Issue of the periodical within the volume

    6

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    7

  • Pages from-to

    1069-1075

  • UT code for WoS article

    000290710800017

  • EID of the result in the Scopus database

    2-s2.0-79956349197